help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dickstein, G. M.
Right arrow Articles by Carey, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dickstein, G. M.
Right arrow Articles by Carey, R. M.

Endocrinology, Vol 117, 2160-2169, Copyright © 1985 by Endocrine Society

ARTICLES

Escape from the sodium-retaining action of intrarenal angiotensins II and III in the conscious dog

GM Dickstein, JF Woodson, NE Lamb, CE Rose Jr, MJ Peach and RM Carey

The maximum amounts of angiotensins II and III that were confined to the kidney during intrarenal arterial administration in conscious dogs were determined to be 2 and 12 pmol/kg X min, respectively. These doses were infused chronically intrarenally to uninephrectomized dogs. A significant reduction in urinary volume and excretion of sodium was observed at 24 h of the intrarenal peptide infusions. These excretory effects were more marked with angiotensin III than with angiotensin II. Escape from the antidiuretic and antinatriuretic effects of angiotensins II and III was observed after 24 h in spite of continuous administration of the peptides. To define the role of reduced intrarenal angiotensin concentration in the physiological phenomenon of escape from the sodium-retaining action of mineralocorticoids, angiotensin II or III at the above doses was administered intrarenally together with 11-deoxycorticosterone acetate. No delay in escape from the sodium-retaining effects of the mineralocorticoid was noted as a result of concurrent intrarenal angiotensin administration. In conclusion, both angiotensin II and angiotensin III have direct sodium- and volume-retaining effects on the kidney. These renal effects are abolished within 48 h, either due to tachyphylaxis to angiotensins or by other mechanisms overriding the actions of angiotensins. No association was demonstrated between suppression of the renin- angiotensin system and escape from mineralocorticoid-induced sodium retention.


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
H. M. Siragy, T. Inagami, T. Ichiki, and R. M. Carey
Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor
PNAS, May 25, 1999; 96(11): 6506 - 6510.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. M. Fitzgerald, K. M. Stevenson, R. G. Evans, and W. P. Anderson
Systemic hemodynamic responses to chronic angiotensin II infusion into the renal artery of dogs
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 1997; 273(6): R1980 - R1989.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
H. M. Siragy, A. A. Jaffa, and H. S. Margolius
Bradykinin B2 Receptor Modulates Renal Prostaglandin E2 and Nitric Oxide
Hypertension, March 1, 1997; 29(3): 757 - 762.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1985 by The Endocrine Society